A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 4, 1998, Pages 255-268

  Hornick, Jason L ^a   Sharifi, Jahangir ^a   Khawli, Leslie A ^a   Hu, Peisheng ^a   Biela, Barbara H ^a   Mizokami, Myra M ^a   Yun, Aoyun ^a   Taylor, Clive R ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biotinylation; Chimeric antibody; Pharmacokinetics; Radioimmunotherapy

Indexed keywords

ANTINUCLEAR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TNT 3; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BIOTINYLATION; COMPARATIVE STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SOLID TUMOR; TUMOR LOCALIZATION;

EID: 0031760730     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.255     Document Type: Article

References (48)

1. Wilder RB, DeNardo GL and DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 11996;4:1383.
2. Bruland OS. Cancer therapy with radiolabeled antibodies. An overview. Acta Oncol 1995;34:1085.
3. Kairemo KJ. Radioimmunotherapy of solid cancers: a review. Acta Oncol 1996;35:343
4. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297.
5. Zhu H, Baxter LT and Jain RK. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 1997;38:731.
6. Buchsbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res (Suppl) 1995,55:5729s.
7. von Mehren M and Weiner LM. Monoclonal antibody-based therapy. Curr Opin Oncol 1996;8:493.
8. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;27:1079.
9. Epstein AL. New approaches to improved antibody targeting. In Henkin RE (ed): Nuclear Medicine. St. Louis, Mosby-Year Book, 1996, p 516.
10. Epstein AL, Khawli LA, Chen F-M, Hu P, Glasky MS and Taylor CR. Tumor necrosis imaging and treatment of solid tumors. In Torchilin VP (ed): Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL, CRC Press, 1995, p 259.
11. 2 monoclonal antibody. Antibody Immunoconj Radiopharm 1991;4:151.
12. Epstein AL, Chen F-M and Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842.
13. Chen F-M, Epstein AL, Li Z and Taylor CR. A comparative autoradiographic study demonstrating differential intratumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens. J Nucl Med 1990;31:1059
14. 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578.
15. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M and Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1994;1:365.
16. Morrison SL, Johnson MJ, Herzenberg LA and Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81.6851.
17. Boulianne GL, Hozumi N and Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984;312:643.
18. Khazaeli MB, Corny RM and LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42
19. Vriesendorp HM, Quadri SM, Andersson BS and Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol 1996;24:1183.
20. Khaw B-A, Klibanov A, O'Donnell SM, Saito T, Nossiff N, Slinkin MA, Newell JB, Strauss HW and Torchilin VP. Gamma imaging with negatively charge-modified monoclonal antibody: modification with synthetic polymers. J Nucl Med 1991;32:1742.
21. John E, Thakur ML, Wilder S, Alauddin MM and Epstein AL Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites. J Nucl Med 1994;35:876.
22. 2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments Circulation 1995;92:474.
23. Khawli LA, Glasky MS, Alauddin MM and Epstein AL. Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. Cancer Biother Radiophar 1996;11:203.
24. Khawli LA and Epstein AL. Exploration of novel strategies to enhance monoclonal antibodies targeting. Q J Nucl Med 1997;41:25.
25. Epstein AL and Clevenger CV. Identification of nuclear antigens in human cells by immunofluorescence, immunoelectron microscopy, and immunobiochemical methods using monoclonal antibodies. In Bekhor I (ed): Recent advances in non-histone chromosomal protein research, vol. 1. Boca Raton, FL, CRC Press, 1985, p 117.
26. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL and Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26.
27. Hu P, Glasky MS, Yun A, Alauddin MM, Homick JL, Khawli LA and Epstein AL. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibod Hybridomas 1995;6:57.
28. Pulvertaft RJV. Cytology of Burkitt's tumour (African lymphoma). Lancet 1964;1:238.
29. Ohsugi Y, Gershwin ME, Owens RB and Nelson-Rees WA. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J Natl Cancer Inst 1980;65:715.
30. Chomczynski P and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156.
31. Orlandi R, Gussow DH, Jones PT and Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833.
32. Jones ST and Bendig MM. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Bio/Technology 1991;9:88.
33. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987;196:947.
34. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680.
35. Green NM. Spectrophotometric determination of avidin and biotin. Meth Enzymol 1970;18A:418.
36. Gaffar SA, Chen F-M, Liu C and Epstein AL. Cell based radioimmunoassays to quantitate the immunoreactivity of TNT monoclonal antibodies directed against intracellular antigens. J Immunoassay 1991;12:1.
37. Epstein AL, Marder RJ, Winter JN and Fox RI. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J Immunol 1984,133.1028.
38. Frankel ME and Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay: an analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol 1979;16:101.
39. Swanson PE. Microwave antigen retrieval in citrate buffer Lab Med 1994;25:520.
40. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986;55:244.
41. Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM and Epstein AL. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997;89:4437.
42. Zuckier LS, Georgescu L, Chang CJ, Scharff MD and Morrison SL. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994;73:794.
43. Miller GK, Naeve GS, Gaffar SA and Epstein AL. Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones. Hybridoma 1993;12:689.
44. Bebbington CR, Renner G, Thomson S, King D, Abrams D and Yarranton GT. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology 1992;10:169.
45. Wadsley JJ and Watt RM. The effect of pH on the aggregation of biotinylated antibodies and on the signal-to-noise observed in immunoassays utilizing biotinylated antibodies. J Immunol Methods 1987;103:1.
46. Gangopadhyay A and Van den Abbeele AD. Modification of mouse IgG isoelectric point following radioiodination. Antibody Immunoconj Radiopharm 1994,7:171.
47. Reisfeld RA and Gillies SD. Recombinant antibody fusion proteins for cancer immunotherapy. Curr Top Microbiol Immunol 1996;213 (Pt 3):27.
48. Becker JC, Varki N, Gillies SD, Furukawa K and Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996,93:7826.